GAROFALO HEALTH CARE S.P.A. financials
GAROFALO HEALTH CARE S.P.A.
Country: IT Reporting currency: EUR Latest annual report: 2025-12-31
LEI:
815600C851C90CAE6438 Financial statements
(EUR, as reported — unscaled; 94 line items across 2 annual periods)
| Line item | 2025 | 2024 |
|---|---|---|
| Income statement | ||
| Revenue | €487.1M | €470.7M |
| Operating expenses | €408.0M | €394.1M |
| Employee benefits expense | €115.0M | €112.3M |
| Raw materials & consumables used | €74.9M | €70.0M |
| Operating profit (EBIT) | €45.1M | €44.1M |
| Net finance income / (cost) | -€11.2M | -€13.4M |
| Finance costs | €11.8M | €14.8M |
| Profit before tax | €34.0M | €30.7M |
| Income tax expense | €10.4M | €8.8M |
| Profit for the year | €23.6M | €21.8M |
| — attributable to owners | €23.4M | €21.7M |
| — attributable to NCI | €159.0K | €146.0K |
| Cash flow statement | ||
| Net cash from operating activities | €49.0M | €35.0M |
| Net cash from investing activities | -€34.0M | -€18.4M |
| Purchase of PP&E (capex) | €30.9M | €18.3M |
| Purchase of intangibles | €2.6M | €3.3M |
| Net cash from financing activities | -€21.8M | -€12.7M |
| Dividends paid | €7.6M | €0 |
| Net change in cash | -€6.8M | €4.0M |
| Balance sheet | ||
| Total assets | €859.8M | €850.2M |
| Non-current assets | €692.3M | €685.7M |
| Property, plant & equipment | €301.4M | €293.8M |
| Intangible assets & goodwill | €91.5M | €91.5M |
| Inventories | €6.2M | €6.1M |
| Trade & other receivables | €117.7M | €112.8M |
| Cash & equivalents | €19.9M | €26.7M |
| Total equity | €349.8M | €333.1M |
| — attributable to owners | €338.9M | €322.4M |
| Non-current liabilities | €373.4M | €372.2M |
| Trade & other payables | €82.2M | €86.4M |
| Deferred tax liabilities | €103.4M | €103.8M |
| Derived metrics | ||
| Free cash flow | €18.1M | €16.7M |
| Operating margin | 9.3% | 9.4% |
| Net margin | 4.8% | 4.6% |
| Return on equity | 6.7% | 6.6% |
| Cash conversion ratio | 2.08× | 1.60× |
| Capex coverage | 1.59× | 1.91× |
| Other reported items | ||
| Accumulated Other Comprehensive Income | €159.0K | -€207.0K |
| Adjustments For Decrease Increase In Inventories | -€148.0K | -€490.0K |
| Adjustments For Decrease Increase In Trade and Other Receivables | -€4.8M | -€12.7M |
| Adjustments For Deferred Tax Expense | €953.0K | €1.7M |
| Adjustments For Depreciation and Amortisation Expense | €27.9M | €25.3M |
| Adjustments For Increase Decrease In Employee Benefit Liabilities | €1.0M | €990.0K |
| Adjustments For Increase Decrease In Trade and Other Payables | -€4.2M | -€1.4M |
| Adjustments For Provisions | €6.1M | €6.3M |
| Adjustments For Undistributed Profits of Investments Accounted For Using Equity Method | -€81.0K | -€123.0K |
| Cash Flows From Used In Increase Decrease In Current Borrowings | -€126.0K | -€16.6M |
| Comprehensive Income Attributable To Noncontrolling Interests | €148.0K | €168.0K |
| Comprehensive Income Attributable To Owners of Parent | €24.8M | €23.2M |
| Current Assets Other Than Assets Or Disposal Groups Classified As Held For Sale Or As Held For Distribution To Owners | €167.6M | €164.5M |
| Current Liabilities Other Than Liabilities Included In Disposal Groups Classified As Held For Sale | €136.6M | €144.8M |
| Current Tax Assets Current | €6.8M | €7.4M |
| Current Tax Liabilities Current | €6.1M | €3.7M |
| Deferred Tax Assets | €12.8M | €14.0M |
| Depreciation Amortisation and Impairment Loss Reversal of Impairment Loss Recognised In Profit Or Loss | €29.0M | €26.2M |
| Dividends Received From Associates Classified As Investing Activities | €0 | €0 |
| Equity and Liabilities | €859.8M | €850.2M |
| Finance Income | €547.0K | €1.2M |
| Income Tax Relating To Remeasurements of Defined Benefit Plans of Other Comprehensive Income | €275.0K | €700.0K |
| Income Taxes Paid Refund | €6.9M | €8.7M |
| Intangible Assets Other Than Goodwill | €281.8M | €281.4M |
| Interest Paid Classified As Financing Activities | €9.6M | €9.8M |
| Investment Property | €311.0K | €810.0K |
| Issue of Equity | €0 | €0 |
| Issued Capital | €31.6M | €31.6M |
| Liabilities | €510.0M | €517.1M |
| Noncurrent Provisions For Employee Benefits | €14.0M | €15.9M |
| Other Adjustments For Noncash Items | €1.9M | €2.5M |
| Other Comprehensive Income | €1.4M | €1.6M |
| Other Comprehensive Income Before Tax Gains Losses On Remeasurements of Defined Benefit Plans | €1.1M | €2.9M |
| Other Comprehensive Income That Will Be Reclassified To Profit Or Loss Net of Tax | €502.0K | -€654.0K |
| Other Comprehensive Income That Will Not Be Reclassified To Profit Or Loss Net of Tax | €871.0K | €2.2M |
| Other Current Financial Assets | €10.5M | €5.5M |
| Other Current Financial Liabilities | €6.2M | €6.8M |
| Other Current Nonfinancial Assets | €6.4M | €6.1M |
| Other Current Nonfinancial Liabilities | €42.1M | €48.0M |
| Other Expense By Nature | €25.8M | €25.1M |
| Other Inflows Outflows of Cash Classified As Financing Activities | -€11.6M | -€12.5M |
| Other Longterm Provisions | €24.6M | €25.6M |
| Other Noncurrent Financial Assets | €1.6M | €1.4M |
| Other Noncurrent Financial Liabilities | €220.2M | €224.4M |
| Other Noncurrent Liabilities | €11.2M | €2.5M |
| Other Noncurrent Nonfinancial Assets | €1.4M | €1.4M |
| Other Revenue | €8.2M | €8.5M |
| Payments To Acquire Or Redeem Entitys Shares | €1.3M | €849.0K |
| Proceeds From Noncurrent Borrowings | €0 | €177.8M |
| Proceeds From Sales of Property Plant and Equipment Classified As Investing Activities | €272.0K | €791.0K |
| Provisions | €24.9M | €23.4M |
| Purchase of Other Longterm Assets Classified As Investing Activities | €810.0K | €0 |
| Repayments of Noncurrent Borrowings | €1.1M | €160.6M |
| Revenue From Contracts With Customers | €478.8M | €462.2M |
| Services Expense | €192.3M | €186.6M |
| Share of Profit Loss of Associates Accounted For Using Equity Method | €81.0K | €123.0K |
| Statutory Reserve | €1.2M | €1.1M |
Methodology
Every line item above is a fact tagged in GAROFALO HEALTH CARE S.P.A.'s annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (EUR), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.